July 21st 2025
Mitomycin intravesical solution was granted FDA approval in June 2025 for recurrent LG-IR-NMIBC.
Neoadjuvant nivolumab plus gemcitabine/cisplatin found safe and efficacious in MIBC
March 16th 2022The BLASST-1 study presented at the 2022 ASCO Genitourinary Cancers Symposium assessed the safety and efficacy of neoadjuvant nivolumab in combination with gemcitabine/cisplatin in patients with muscle-invasive bladder cancer .
Urology Times 50 Innovations Series: BCG therapy for bladder cancer
March 16th 2022"It is clearly the standard and it's the treatment of choice. When you have that, and it's very good, it's evidenced by the fact that none of the agents are compared against BCG because it sets such a high standard of effectiveness," says Sam S. Chang, MD, MBA.
How Botox is changing the landscape of urologic treatment
March 14th 2022Min Dong, PhD, discusses the main points of the presentation he gave at the 2022 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting, along with the potential impact of onabotulinumtoxinA (Botox) therapies on future urologic treatment.
Impact of cisplatin ineligibility on receiving adjuvant therapy for UTUC
February 15th 2022Shawn Dason, MD, discusses the findings and takeaways of the study, "How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?"
Study demonstrates feasibility of antegrade instillation of Jelmyto for UTUC
February 11th 2022“While Jelmyto is approved for both retrograde and antegrade instillation, the instructions for administration address retrograde instillation, and this is the first time that data on antegrade instillation has been documented in a clinical setting for this chemoablative therapy,” said Katie Murray, DO.
Gender disparities found in bladder cancer trials and real-world systemic therapy use
February 8th 2022“We have to be more mindful and thoughtful about the fact that certain populations are underrepresented in clinical trials, and that’s likely due to a number of factors,” said co-author Padraic O’Malley, MD, MSc, FRCSC.